ABSTRACT. Developing a promising carrier for the delivery of poorly water-soluble drugs, such as silybin, to improve oral absorption has become a very worthy of consideration. The goal of this study was to prepare a novel porous calcium phosphate microparticle using povidone-mixed micelles as template while evaluating its in vitro and in vivo properties with silybin as a model drug. The particle characterization, in vitro drug release behavior, and pharmacokinetic parameters of the prepared silybin-loaded calcium phosphate microparticle were investigated. The mean particle size was found to be 3.54±0.32 μm with a rough surface porous structure. Additionally, the silybin-loaded calcium phosphate microparticle compared with the free silybin showed a prolonged 72-h release in vitro and a higher C max (418.5± 23.7 ng mL −1 ) with 167.5% oral relative bioavailability. A level A in vitro-in vivo correlation (IVIVC), established for the first time, demonstrated an excellent IVIVC of the formulated silybin in oral administration. In conclusion, this povidone-mixed micelle-based microparticle was successfully prepared to enhance the oral bioavailability of silybin. Therefore, application of this novel porous calcium phosphate microparticle holds a significant potential for the development of poorly water-soluble drugs.
INTRODUCTION
Calcium phosphate has been extensively researched as the biocompatible inorganic biomaterial for synthetic bone grafts (1) and non-viral vectors for gene delivery (2) . Over the past decades, the application of porous calcium phosphate as carriers in drug delivery has attracted much attention due to significant advantages such as large specific surface area and high loading capacity for drug (3) , protein (4, 5) , or DNA molecules (6, 7) . Among the application methods which include micelle-templated synthesis (8, 9) , emulsion process (10) (11) (12) , and surfactant-assisted route (13, 14) , micelletemplated synthesis technique has been the most widely used. To date, polymeric micelle templates have been successfully applied to the fabrication of many porous calcium phosphate carriers. One salient feature of such carriers prepared with micelle-templated method is the ease to tune size and morphology by adjusting the polymer combination, mineralization time, and solvent composition. Afterwards, the micelle template can be removed by calcination or solvent evaporation, leading to a porous or hollow structure.
The key to a successful micelle-templated synthesis is to prepare a proper micelle as template. Our previous work on the polyvinylpyrrolidone (PVP)/sodium cholate/phospholipid mixed (povidone-mixed) micelle (15, 16) established it as a novel carrier which was good at improving the solubility and oral bioavailability of poorly water-soluble drugs. Also, the auxiliary material PVP, a water-soluble nonionic polymer, has a long history in pharmaceutical application as a delivery system for hydrophobic drugs (17) . Besides, the bile salts have been shown to enhance the solubility of hydrophobic drugs (18, 19) . Hence, with the aid of such a micelle system, a controlled architecture of calcium phosphate with porous or hollow structure could be designed to facilitate drug delivery. Thus, the present study aimed at obtaining a porous calcium phosphate carrier for hydrophobic drugs by a new type of polymeric micelle and focused on developing a promising oral carrier for potential applications to improve the delivery of poorly water-soluble drugs in vitro and in vivo.
Despite increasing interests of calcium phosphate carriers in drug delivery (20, 21) , very limited numbers of studies regarding its oral administration exist. Therefore, to evaluate its drug release and oral administration efficiencies, silybin, a naturally occurring polyphenolic flavonoid extracted from the seed of the milk thistle (Silybum marianum) (22, 23) , was incorporated into the calcium phosphate micron-sized carrier as a model drug in this work. Silybin has been widely used for the treatment of liver disorders (24, 25) , such as chronic active hepatitis, hepatic cirrhosis, as well as alcohol-, drug-, and toxin-induced liver damage (26, 27) .
Herein, attempts at preparing a novel calcium phosphate micron-sized carrier based on povidone-mixed micelle (16) to improve in vitro release and oral bioavailability of the poorly water-soluble drug, silybin, have been carried out in this work.
MATERIALS AND METHODS

Materials
Phospholipid was purchased from Taiwei Pharmaceutical Industry Co., Ltd (Shanghai, China). Sodium cholate, disodium hydrogen phosphate, and calcium chloride were obtained from Sinopharm Chemical Reagent Co., Ltd (Shanghai, China). PVP K30 of pharmaceutical grade (Mw∼45,000) was purchased from Sunpower New Material Co., Ltd (Shanghai, China). Silybin (purity≥98%) was kindly provided by Zhongxing Pharmaceutical Industry Co., Ltd (Jiangsu, China). α-Naphthol was purchased from Tianjin Chemical Reagent Factory (Tianjin, China). Other chemical reagents were of analytical grade or better. Male beagle dogs (2 years old, weighing 10.1±1.9 kg) were purchased from Yadong Laboratory Animal Research Center (Jiangsu, China). All the experimental protocols involving animals in this study were evaluated and approved by the Ethics Committee of Jiangsu University on March 2, 2013. The number of the certification which verified approval of this study is 20130302-1.
Preparation of Calcium Phosphate Microparticles
Calcium phosphate microparticles were prepared according to our previous studies (28) . In brief, absolute ethanol solution (20 mL) containing sodium cholate (0.7 g) and phospholipid (0.3 g) was added to 50 mM CaCl 2 aqueous solution (60 mL) and stirred vigorously at 40°C for 10 min. Na 2 HPO 4 (50 mM, 40 mL) and absolute ethanol solution (20 mL) containing PVP K30 (0.4 g) were added drop-wise to the mixture. The suspension obtained was then stirred at 600 rpm for 12 h. The resulting white precipitate was collected and washed thrice by centrifugation-redispersion cycles with deionized water and absolute ethanol. Finally, the collected precipitates were freeze-dried to obtain the powder of calcium phosphate microparticles.
Preparation of Silybin-Loaded Calcium Phosphate Microparticles
The calcium phosphate microparticles were suspended in deionized water to obtain a concentration of 50 mg mL . Then, a 100-mg mL −1 silybin solution was prepared using absolute ethanol as solvent. The calcium phosphate microparticles and silybin solution were mixed at the proportion of 2:1 (v/v) at 37°C and stirred at 600 rpm for 12 h. After centrifugation for 10 min at 15,000 rpm and washing three times with absolute ethanol, the silybin-loaded calcium phosphate microparticles were collected. The powders of silybin-loaded calcium phosphate microparticles were obtained by a freeze-drying process and kept at 4°C for further evaluation.
Particle Size Analysis
Dynamic light scattering measurement was carried out to determine the particle size distribution of calcium phosphate microparticle suspension in deionized water (3 mL, 10 mg mL −1 ) using BIC90 Nanoparticle Size Analyzer (Brookhaven Instruments, USA) at 25°C. The mean particle size was analyzed by the dispersion technology software (Brookhaven Instruments, USA). All assays were performed in triplicate.
Scanning Electron Microscopy (SEM)
The powders of calcium phosphate microparticles were platinum coated with thickness in the range of 3-5 nm. The SEM images of calcium phosphate microparticles were recorded using a JSM 7001F scanning electron microscope (JEOL, Japan) at a working distance of 8 mm and an acceleration voltage of 15 kV.
Fourier Transform Infrared Spectroscopy (FTIR)
To confirm the successful incorporation of silybin, the FTIR spectral measurements were performed using a Nicolet spectrophotometer (Model Avatar 370, Milwaukee, WI, USA). The samples were finely ground with KBr to prepare the pellets under a hydraulic pressure of 8 mPa, and the spectra were scanned between 400 and 4000 cm −1 .
Drug Loading
The silybin-loaded calcium phosphate microparticles were washed thrice with absolute ethanol to dissolve the unloaded silybin. The volume of the eluent was determined and, after diluting to a suitable concentration, the resulting ethanol solution was analyzed by UV at 288 nm, according to the previous literature (29) . The absorbance recorded was applied to a standard curve formula to calculate the concentration of silybin in the ethanol solution. The standard curve formula (A=0.042236C−0.0043510 (n=6, r=0.99939) where A was the absorbance at 288 nm and C represented the concentration of silybin) was established by determining the absorbance of a series of standard silybin ethanol solutions (1, 5, 10, 15, 20 , and 30 μg mL −1 ). The data of drug loading presented as mean of triplicate samples was calculated according to the following equation:
where W was the total weight of drug-loaded calcium phosphate microparticles, W 1 was the weight of drug which was used to prepare the sample of silybin-loaded calcium phosphate microparticles, and W 2 was the weight of drug in the eluent.
In Vitro Drug Release
The in vitro release of silybin-loaded calcium phosphate microparticles and free silybin were investigated with a dialysis method in two different media, phosphate buffer solution (pH 7.4) and HCl solution (pH 1.2), using a ZRS-8G dissolution test apparatus (Tianjin Tianda Tianfa, China). Sample powder (50 mg) was dispersed in 1 mL of each dissolution medium, before placing in dialysis bag (Mw∼3500). The dialysis bag was placed in the basket before immersing in 900 mL of media at 37±0.5°C with a rotational paddle speed of 100± 2 rpm. At settled time intervals (0.5, 1, 2, 3, 6, 8, 12, 24, 36, 48, 60, and 72 h), the dissolution medium of 5 mL was withdrawn and replaced with equal volume of fresh medium (preheated to 37°C). The samples at each time points were filtered through 0.45 μm cellulose nitrate membranes for UV analysis at 288 nm. The calibration tests made with UV absorption measurements of pure silybin at different pH values showed no change in the drug spectra. The cumulative release (%) was calculated as the weight ratio of released silybin to total silybin. Data at each time point were presented as mean of triplicate samples.
Bioavailability of Silybin-Loaded Calcium Phosphate Microparticles in Beagle Dogs
Four male beagle dogs were randomly and equally divided into two groups. The beagle dogs were housed individually and acclimatized in the laboratory for at least 1 week prior to testing. Each dog was fasted for 24 h with free access to water before the experiment. Capsules filled with silybin-loaded calcium phosphate microparticle (at a dose of 20 mg kg −1 silybin) and free silybin were orally administered to each group of dogs, respectively. The washout period between two consecutive treatments was 2 weeks. After oral administration, 2 mL of blood samples was collected from the jugular vein into a heparinized tube at each time point of 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h. The plasma obtained after centrifugation (10 min, 3000 rpm) was stored immediately at −20°C until analysis. Silybin in 200 μL of dog plasma was extracted by the addition of 20 μL internal standard solution (α-naphthol, 10 μg mL
, pH 5), 20 μL methanol, and 5 mL diethyl ether. The mixture was vortex-mixed thoroughly for 5 min and then centrifuged for 10 min at 3000 rpm. The organic phase (4 mL) was quantitatively transferred and evaporated to dryness under a nitrogen flow at 37°C. The dried residue was re-suspended in 100 μL mobile phase. The re-suspended solution (20 μL) was injected into an HPLC system. A Symmetry C18 reserved phase analytical column (5 μm, 4.6 mm ×150 mm, Waters, USA) set at 38°C was employed. The mobile phase was a mixture of methanol and 0.05 mol L −1 KH 2 PO 4 (v/v 1:1, pH adjusted to 3.8 with phosphoric acid) at 1.0 mL min −1 flow rate. The UV detection wavelength was set at 288 nm. The calibration was linear over a range from 10 to 1000 ng mL −1 (R=0.0014297C−0.010905) with a correlation coefficient (r) 0.99851. The LOD of current assay based on S/N=3 was 3 ng mL −1 in plasma. The method recoveries were all above 80% at high, middle, and low concentrations, and the intraand inter-day variation was below to 10.0%. Since silybin is an isomeric compound, two peaks with the retention time were detected (30) . The sum of the area of the two peaks was calculated for analysis. The ratio of peak area of silybin over that of the internal standard was used for quantitative analysis. And the method was validated by adding various quantities of silybin to blank beagle dog plasma. These calibrations were subjected to the entire analytical procedure, so as to test the linearity, precision, and accuracy of the method. The peak concentration (C max ) and peak time (T max ) were derived directly from the experimental points. The relative bioavailability and other pharmacokinetic parameters were calculated using the program BAPP 2.3 (supplied by the Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University) by non-compartmental analysis.
In Vitro-In Vivo Correlation
In this study, a plot of percent dissolved in vitro vs. percent absorbed in vivo input at various time points up to Fig. 1 . Scanning electron micrograph of a calcium phosphate microparticles without micelle template, b porous calcium phosphate microparticles at ×1000 magnification, and c calcium phosphate microparticles at ×10,000 magnification Fig. 2 . Chemical structure of isomeric silybin: a silybin A, b silybin B 24 h was constructed to develop a level A correlation as classified by US Food and Drug Administration (31) . Also, the correlation between in vitro release in two dissolution media (pH 7.4 phosphate buffer solution and pH 1.2 HCl solution) and the in vivo absorption was respectively established.
Statistical Analysis
All the experimental data were expressed as mean± standard deviation (SD), and the statistical differences between the different groups were evaluated by Student's t test. The SPSS statistic software (SPSS version 15.0, SPSS Inc., Chicago, IL, USA) was used. Difference between two groups was considered to be statistically significant at p<0.05. Figure 1 illustrates SEM of the surface and integral morphology of the calcium phosphate microparticles. Significant differences were observed between Fig. 1a and b , which depicted the calcium phosphate microparticles without the micelle template and the porous calcium phosphate microparticles, respectively. Apparently, the calcium phosphate microparticles exhibited spherical or ellipsoidal shape with rough surfaces (Fig. 1b) . A closer view of the micronsized calcium phosphate carrier revealed a nest-like structure on the surface with particle size around 3.5 μm (Fig. 1c) . This indicated an irregular porous structure resulting from the crystal assembling based on the Fig. 3 . FTIR spectra of a calcium phosphate microparticles, b silybin, and c silybin-loaded calcium phosphate microparticles povidone-mixed micelle template. From the structure of silybin presented in Fig. 2 and the FTIR spectra shown in Fig. 3 , characteristic phosphate group bands (Fig. 3a) occurred at wave numbers 561, 601, 961, 1029, and 1120 cm −1 for the calcium phosphate microparticles. The bands at 1029 and 1120 cm −1 could be assigned to the components of triply degenerate ν 3 antisymmetric P-O stretching mode. The non-degenerate P-O symmetric stretching mode ν 2 was detected at 961 cm −1 . The bands at 601 and 561 cm −1 could also be attributed to the components of the triply degenerated ν 1 O-P-O bending mode. The FTIR spectra in Fig. 3b indicated characteristic group bands at wave numbers 1272, 1511, 1639, 2929, and 3450 cm −1 for free silybin. The broader band at 3450 cm −1 was attributed to the hydroxyl groups, while the bands at 2929, 1639, 1272, and 1511 cm −1 were assigned to C-H, C=O, C-O, and C=C stretching modes, respectively, which proved the existence of benzene ring. The FTIR spectra in Fig. 3c showed both characteristic group bands of calcium phosphate and silybin. The bands at wave numbers 561, 601, 961, 1028, and 1120 cm −1 in the spectra indicated the presence of calcium phosphate. The characteristic groups of silybin could be assigned to the bands at wave numbers 1278, 1507, and 1635 cm ). These results suggest that silybin was loaded into the porous structure of calcium phosphate microparticles. The content of loaded silybin was calculated to be 44.6±1.2%. Figure 4 showed the dissolution profiles of silybin-loaded calcium phosphate microparticles and free silybin in HCl solution (pH 1.2) and phosphate buffer solution (pH 7.4).Less than 21.7% of the free silybin (suspended in 1 mL of the dissolution medium) in the dialysis bag was released within 72 h as compared to 65.2% from the calcium phosphate microparticles. The respective cumulative drug release of 13.4% and 42.8% from free silybin and the microparticle in HCl solution (pH 1.2) within 72 h was relatively slower as compared with that from the phosphate buffer saline (pH 7.4) over the same period. These results suggest that the release of silybin in this study was pH-dependent, with higher pH values leading to faster drug release. Data are shown as mean ± SD MRT mean residence time, AUC area under curve
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In vivo pharmacokinetic study for free silybin and silybinloaded calcium phosphate microparticles was conducted in beagle dogs. Plasma concentration versus time profiles of silybin following oral administration of silybin-loaded calcium phosphate microparticles and free silybin are depicted in Fig. 5 . The pharmacokinetic parameters simulated by noncompartmental model using software program BAPP 2.3 are also shown in Table I . As illustrated in the profile, the average value of C max after oral administration of silybin-loaded calcium phosphate microparticles was 418.5±23.7 ng mL −1 with T max of about 4 h as compared with C max of 112.4 ± 8.4 ng mL −1 and T max of about 2 h from the free silybin. In addition, the relative bioavailability of silybin-loaded calcium phosphate microparticles in contrast with free silybin was about 167.5%.
In Vitro-In Vivo Correlation
In this study, the correlation between in vitro and in vivo data for the prepared calcium phosphate microparticles was investigated. A level A correlation (32), i.e., a point-to-point relationship between in vitro dissolution and in vivo absorption, was established in HCl solution (pH 1.2) and phosphate buffer solution (pH 7.4). As can be seen from Fig. 6 , an excellent correlation was obtained with r=0.98917 for the phosphate buffer solution and r=0.98737 for HCl solution.
DISCUSSION
Povidone-mixed micelle system was initially designed to improve the solubility and oral bioavailability of poorly soluble drugs. PVP is a water-soluble nonionic polymer, which has a long history of use in pharmaceutical applications as a delivery system for poorly soluble drugs (33) . Addition of PVP has been shown to increase the solubility and dissolution rates of certain poorly soluble drugs (34) . In this study, the povidone-mixed micelle system was adopted innovatively as a new type of template to fabricate the calcium phosphate micron-sized carrier, which was incorporated with the hydrophobic drug, silybin, to evaluate oral bioavailability. As shown in Fig. 6 , SEM images demonstrated the calcium phosphate carrier was well dispersed as individual particles. The particle size (3.5 μm) observed from the SEM was consistent with that determined by the particle detector. Furthermore, the calcium phosphate micron-sized carrier exhibited spherical or ellipsoidal shape with a rough surface, which suggested an irregular porous structure, thus proving that the micelle template was removed by solvent evaporation over a gentle temperature condition of 40°C. As shown in Fig. 6 , the FTIR spectra confirmed the existence of calcium phosphate. The disappearance and decrease in spectra of drug-loaded calcium phosphate carrier at certain group bands of silybin indicated the incorporation of silybin into the porous structure.
As pointed out in our previous study, the dissolution of free silybin was pH-dependent which increased with increasing pH (15, 16) . In the present work, the drug release behavior of calcium phosphate carrier was conducted in different pH solution. It can be seen from Fig. 6 that the dissolution profile exhibited a faster release from the calcium phosphate carrier than free silybin, while the both release accelerated with increasing pH. The release behavior of silybin from the calcium phosphate microparticles was consistent with our previous findings. Therefore, the pH-dependent behavior might indicate the removal of templated micelles. The pH-dependent behavior of silybin-loaded calcium phosphate microparticles could mainly be attributed to the silybin itself. The dissolution rate from calcium phosphate carriers was markedly different due to the different templates involved, some exhibited a very fast release behavior (35) while others exhibited a slow release behavior (3) .
The pharmacokinetics of silybin-loaded calcium phosphate carrier and free silybin after orally administrated to beagle dogs were also investigated in this work. As observed from the profile of plasma concentration versus time depicted in Fig. 6 and the pharmacokinetic parameters shown in Table I , free silybin exhibited a very low bioavailability, which was in conformity with the results previously reported (36, 37) . Meanwhile, the clinical efficacy of silybin is discounted by its poor water solubility, which result in poor oral absorption and bioavailability. Additionally, obvious differences between free silybin and silybin-loaded calcium phosphate carrier were found with respect to the delayed T max from 2 to 4 h. Moreover, the peak concentration of silybin release was approximately 3.7-fold of the free silybin after it had been incorporated into the calcium phosphate carrier. The main reason for the delay in T max may be ascribed to the materials which we used for preparing the calcium phosphate microparticles. After the drug was incorporated into this carrier, it was protected by the microparticle matrix from the rapid degradation at acidic pH conditions. Notably, a tiny peak was observed at 10 h, which may be due to the effect of bile salt via the enterohepatic circulation, as evidenced by Wu et al. (38) . The relative bioavailability of 167.5% for silybin-loaded calcium phosphate carrier was dramatically enhanced compared to the free silybin. However, no significant difference was found in t 1/2 and MRT between the two experimental groups. As we know, the micellar system has been extensively investigated due to its advantage in improving the solubility and enhancing the oral bioavailability of poorly water-soluble drug. In our experiment, the calcium phosphate microparticle designed from povidone/ sodium cholate/phospholipid mixed micelles was successfully prepared, and the drug was proven to be incorporated into the porous structure after the removal of the micellar template, thus leading to prolonged release in vitro and enhanced absorption in vivo. On the other hand, the improved oral bioavailability of silybin-loaded microparticle might be attributed to enhanced silybin solubility in the gastrointestinal tract and relatively small size (39) . Additionally, the drug was expected to be highly dispersed with high drug loading content in the prepared microparticle system due to the porous structure of the calcium phosphate microparticle.
The in vitro-in vivo correlation analysis of silybin-loaded calcium carbonate nanoparticles in two different media (phosphate buffer solution (pH 7.4) and HCl solution (pH 1.2)) showed an excellent linear relationship, with no significant influences of different pH values. This excellent correlation is quite important since it could suggest the possibility to predict in vivo pharmacokinetic behavior through the observed in vitro release profiles (40) .
CONCLUSION
In summary, a novel porous calcium phosphate microparticle based on povidone/sodium cholate/phospholipid mixed micelles was prepared successfully for the first time. The pharmacokinetic study in beagle dogs showed the enhanced oral bioavailability facilitated by the prepared microparticle. The findings support the ability of porous calcium phosphate microparticle to improve solubility and oral bioavailability, thus advancing the literature of drug delivery for poorly water-soluble drugs.
